The FDA has only approved one medical wearable that provides continuous oxygen saturation (SpO2) and pulse rate tracking: the Masimo W1 Medical watch. “If you really want a wearable that’s ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

Masimo (NASDAQ: MASI) today announced that Vanderbilt University Medical Center (VUMC), a renowned healthcare facility in ...

which started with the Masimo’s claim that its patents had been infringed by the Apple Watch’s pulse-oximetry feature, which allows Watch owners to measure their blood oxygen levels.

The lawsuit resulted in five of Masimo’s claims being rejected, and a jury being unable to reach agreement on the rest. That will see a new trial held, at a date yet to be set. Masimo got its ...

Masimo has previously accused Apple of hiring away its employees and copying aspects of its pulse oximetry technology following failed collaboration talks. Masimo scored a significant victory in ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Irvine, California-based Masimo accused Apple of hiring away its employees and stealing its pulse oximetry technology after discussing a potential collaboration. Masimo convinced the U.S ...